HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- (4- methyl- 2- thiazolylazo)- 5- diethylaminophenol

stain for cadmium chelates

Also Known As:

METADAP

Networked: 7 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Azo Compounds: 333
  - 2-(4-methyl-2-thiazolylazo)-5-diethylaminophenol: 7

Experts

1.	Becquemont, Laurent: 6 articles (01/2020 - 10/2015)
2.	Colle, Romain: 6 articles (01/2020 - 10/2015)
3.	Corruble, Emmanuelle: 6 articles (01/2020 - 10/2015)
4.	Verstuyft, Céline: 5 articles (12/2018 - 10/2015)
5.	Fève, Bruno: 4 articles (01/2020 - 10/2015)
6.	Falissard, Bruno: 4 articles (12/2018 - 10/2015)
7.	Ferreri, Florian: 4 articles (12/2018 - 10/2015)
8.	Haffen, Emmanuel: 4 articles (12/2018 - 10/2015)
9.	Polosan, Mircea: 4 articles (12/2018 - 10/2015)
10.	Chanson, Philippe: 3 articles (12/2018 - 10/2015)

Related Diseases

1.	Major Depressive Disorder (Major Depressive Disorders) 01/01/2018 - "In 624 patients currently experiencing an MDE in the context of Major Depressive Disorder (MDD) (METADAP study), we assessed the association between 8 TRKB genetic polymorphisms (rs1778933, rs1187352, rs2289658, rs2289657, rs2289656, rs3824519, rs56142442 and rs1439050) and acute (previous month) or past (older than one month) SA. " 01/01/2017 - "We used the baseline data of the METADAP cohort, comprising 624 patients with a current MDE in a context of Major Depressive Disorder treated in psychiatry settings, without current alcohol use disorders. " 12/01/2018 - "In the 6-month prospective METADAP cohort, 260 non-overweight patients with a Major Depressive Disorder (MDD) and a current Major Depressive Episode (MDE) were assessed for early weight gain (>5%) after one month of treatment, and for the later incidence of MetS after three and six months of treatment. " 12/01/2018 - "In the six month prospective METADAP cohort, 260 non-overweight patients with a major depressive disorder (MDD), who have recently experienced a Major Depressive Episode (MDE) were assessed for early weight gain (>3%,>5%, and >7%) after one month of treatment, and for long term weight gain (>15% and >20%) after three and six months of treatment. "
2.	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/01/2020 - "Severe insomnia is associated with metabolic syndrome in women over 50 years with major depression treated in psychiatry settings: a METADAP report." 10/01/2015 - "Treating major depressive episodes with antidepressants can induce or worsen metabolic syndrome: results of the METADAP cohort." 01/11/2023 - "Non-overweight depressed patients who respond to antidepressant treatment have a higher risk of later metabolic syndrome: findings from the METADAP cohort." 12/01/2018 - "Early weight gain predicts later metabolic syndrome in depressed patients treated with antidepressants: Findings from the METADAP cohort."
3.	Overweight 01/11/2023 - "In the 6-month prospective METADAP cohort, non-overweight patients, body mass index <25 kg/m2, with MDD and a current MDE were assessed for treatment response after 3 months of treatment, and incidence of MetS after 3 and 6 months of treatment. " 01/11/2023 - "Non-overweight depressed patients who respond to antidepressant treatment have a higher risk of later metabolic syndrome: findings from the METADAP cohort." 12/01/2018 - "In the 6-month prospective METADAP cohort, 260 non-overweight patients with a Major Depressive Disorder (MDD) and a current Major Depressive Episode (MDE) were assessed for early weight gain (>5%) after one month of treatment, and for the later incidence of MetS after three and six months of treatment. " 12/01/2018 - "In the six month prospective METADAP cohort, 260 non-overweight patients with a major depressive disorder (MDD), who have recently experienced a Major Depressive Episode (MDE) were assessed for early weight gain (>3%,>5%, and >7%) after one month of treatment, and for long term weight gain (>15% and >20%) after three and six months of treatment. "
4.	Weight Gain 12/01/2018 - "Early weight gain predicts later weight gain in depressed patients treated with antidepressants: Findings from the METADAP cohort." 12/01/2018 - "Early weight gain predicts later metabolic syndrome in depressed patients treated with antidepressants: Findings from the METADAP cohort." 12/01/2018 - "In the 6-month prospective METADAP cohort, 260 non-overweight patients with a Major Depressive Disorder (MDD) and a current Major Depressive Episode (MDE) were assessed for early weight gain (>5%) after one month of treatment, and for the later incidence of MetS after three and six months of treatment. " 12/01/2018 - "In the six month prospective METADAP cohort, 260 non-overweight patients with a major depressive disorder (MDD), who have recently experienced a Major Depressive Episode (MDE) were assessed for early weight gain (>3%,>5%, and >7%) after one month of treatment, and for long term weight gain (>15% and >20%) after three and six months of treatment. "
5.	Sleep Initiation and Maintenance Disorders (Insomnia) 01/01/2020 - "Severe insomnia is associated with metabolic syndrome in women over 50 years with major depression treated in psychiatry settings: a METADAP report."

Related Drugs and Biologics

1.	3,4-methylenedioxyethamphetamine (MDEA)
2.	Antidepressive Agents (Antidepressants)